We use cookies to help provide you with the best possible online experience. Learn more

Press archive

    Machine Learning and latest RayCare innovations on show at ESTRO 37

    PDF

    During 20–24 April, RaySearch will be exhibiting at the ESTRO 37 congress in Barcelona, Spain. In addition to the latest advances in machine learning technology* and online adaptive therapy, RaySearch will demonstrate the latest innovations in the groundbreaking RayCare™* oncology information system, which has now been released. RaySearch will also show the new features available in the latest release of its treatment planning system, RayStation®. Attendees are welcome to visit RaySearch at booth #1000, and demonstrations can be booked now at: www.raysearchlabs.com.

    New features in RayStation 7*
    New functionality and a wide range of general improvements will be on show. The latest RayStation release that will be demonstrated contains several enhancements to existing functionality that will contribute to improved workflows and planning efficiency, including integration with RayCare, the next-generation oncology information system. Major new functionality includes the addition of robust constraints in multi-criteria optimization (MCO), simulated organ motion for robust optimization and evaluation, multi-atlas-based segmentation and conformal arc planning for photons. 

    Significant additions on the proton side include support for Hyperscan™ pencil beam scanning technology from Mevion Medical Systems, and support for uniform scanning for proton therapy systems from Mitsubishi Electric. Other proton therapy improvements include snout rotation for passive proton techniques and MLC collimation for PBS and passive techniques. 

    RayCare: the next-generation oncology information system
    RayCare 1 was launched in December 2017 and is already in clinical use at Iridium Cancer Network in Belgium. Iridium will present its first experiences with the system during the RaySearch lunch symposium on Saturday 21 April.

    Development of upcoming versions of RayCare is going forward rapidly. RaySearch will demonstrate the latest improvements and features, including advanced workflow management tools and integrated planning workflow support for RayStation. RayCare active workflows are highly configurable and the task management features enable an integrated planning experience with RayStation, supporting automation of process steps and communication around planning tasks.

    Other features on show include the built-in PACS system, which supports automation of imaging workflows, and the control room client for radiation therapy treatment management.

    Machine Learning demonstrations
    The Machine Learning department at RaySearch is developing solutions for automating workflows and supporting the user in RayStation and RayCare. At ESTRO 37, RaySearch will demonstrate two RayStation applications of machine learning: automated treatment planning and automated organ segmentation. The automated planning application uses machine learning algorithms to generate a set of treatment plans in minutes, based on clinical treatment data from Princess Margaret Cancer Centre and University Medical Centre Groningen. Automated organ segmentation uses deep neural networks to generate a set of 3D organ volumes within seconds.

    RaySearch will also present the machine learning and analytics framework concept that will enable RayStation and RayCare to become learning systems.

    Lunch symposium: Advancing Cancer Treatment Through Software Innovation
    On Saturday April 21, 13:15 - 14:15, floor P1, room 11, RaySearch will hold a lunch symposium focused on how software is driving innovation in oncology.
    Moderator: Rik Westendorp, Medical Physicist, Radiotherapiegroep, Deventer, Holland

    Fight cancer with code
    Johan Löf, Founder & CEO, RaySearch Laboratories (publ), Stockholm, Sweden

    First clinical experience with RayCare 1 in a multi-institutional setting
    Carole Mercier, Radiation Oncologist, Iridium Cancer Network, Belgium

    Efficiency improvements with RayStation
    Nick West, Lead Clinical Scientist, The Northern Centre for Cancer Care, Newcastle, UK

    Questions and conclusion session
    Rik Westendorp, Medical Physicist, Radiotherapiegroep, Deventer, Holland

        
      
    About RayCare

    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    More information about RaySearch is available at www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    PDF

    RaySearch and IBA to demonstrate first online adaptive proton workflow at ESTRO

    PDF

    RaySearch, the global leader in software for cancer treatment, and IBA, the world’s leading provider of proton therapy solutions for the treatment of cancer, will make a unique joint presentation at the ESTRO 37 Annual Meeting. The companies will demonstrate their innovative approach to optimizing the patient treatment workflow through the first online adaptive proton therapy workflow.

    The comprehensive demonstration will feature the oncology information system RayCare* and the treatment planning system RayStation from RaySearch, in combination with IBA’s adaPT Treatment Suite, composed of the adaPT Insight imaging platform and adaPT Deliver for treatment delivery.

    In an online adaptive workflow, daily cone beam images are taken and matched to the planning CT for a particular patient. Based on the daily images, an updated treatment plan can be automatically suggested to the care team at the time of a treatment session. A plan adaptation that takes the patient’s current situation into account can thus be made before treatment delivery starts. This workflow benefits patients by allowing for more accurate treatments and faster plan adaptation.

    Frederic Genin, Head of Product Management at IBA, says: “The combination of IBA’s most advanced cone beam imaging solutions and RaySearch’s treatment planning and oncology information systems will enable our future clinical partners to make online adaptive proton therapy a reality. We are very excited to see how these advanced capabilities will benefit patients around the world.”

    Björn Hårdemark, Deputy CEO of RaySearch, says: “The treatment planning technologies necessary for adaptive re-planning have long been available in RayStation, and the introduction of RayCare added the workflow components for offline adaptive treatments. Online adaptive treatment demands a tight integration of the delivery systems, and the strategic alliance between IBA and RaySearch makes this possible. This successful integration clearly shows the strength of a collaborative approach.”

    The live demonstration of the first online adaptive proton therapy workflow will take place at the IBA booth, #1400, during the ESTRO Annual Meeting in Barcelona, Spain, 20–24 April 2018.

    About IBA
    IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

    About RayCare
    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    More information about RaySearch is available at www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    PDF

    RayStation users win treatment planning World Championships

    PDF

    In the first World Championships of Treatment Planning, arranged by ProKnow, RayStation users scored highest in two out of three planning categories. The categories were proton, VMAT and IMRT. RayStation users reached five of the ten highest scores, with all submitted plans taken into consideration. This is particularly impressive, since the next-best TPS that was used in preparing the dose planning, contributed with more than twice as many plans in comparison to RayStation.

    RayStation user Dennie Fransen, Senior Radiation Therapy Technologist at Holland Proton Therapy Centre (HollandPTC), scored highest in the proton category, with all submitted plans considered. Fransen has extensive experience in treatment planning with several different planning systems and treatment techniques. Over the last 18 months, he has been using RayStation for intensity modulated proton therapy, which is one of the most advanced and accurate radiation therapy techniques.
    "Participating in the inaugural World Championships in treatment planning was a fun experience. The ability to quickly produce high quality proton plans in RayStation was a key factor for this competition”, says Dennie Fransen.

    In the IMRT category, RaySearch research engineer Björn Andersson achieved the highest score using an automatic planning technique that he recently developed, which will be included in a future RayStation release*.
    The winning plan was thus produced with only minimal user interaction. After the competition had closed, the automatic planning technique was applied to the proton and VMAT categories as well, showing good results.
    "I am of course delighted that my technique managed to produce a winning plan. Looking forward, I am very excited about the possibilities that automatic treatment planning will bring to radiation therapy", says Björn Andersson.

    Björn Hårdemark, Deputy CEO at RaySearch, says: “I’m happy to see that RayStation users have once again achieved excellent scores in a global treatment planning competition. ProKnow has done an excellent job in creating the scenarios and scoring criteria to achieve a fair and exciting competition, and it will be interesting to monitor the impact of automatic planning techniques in future events.”

    About ProKnow World Championships:
    The objective of the World Championships of treatment planning is to determine what planner and planning system can produce the highest quality plan in an aggressive and limited timeframe. Professionals from over 30 countries participated.
    For more information about the competition, please visit: https://proknowsystems.com/

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com 

    PDF

    RayStation selected for Proton and Carbon Ion Therapy centers in Heidelberg and Marburg, Germany

    PDF

    RayStation* has been chosen as the treatment planning system for Heidelberg Ion Beam Therapy Center (HIT) and Marburg Ion Beam Therapy Center (MIT) – The new order means that all carbon ion therapy centers in Europe have selected RayStation.

    Heidelberger Ionenstrahl-Therapiezentrum (HIT) and Marburger Ionenstrahl-Therapiezentrum (MIT) in Germany is both operational with protons and carbon ions and operates similar accelerator systems provided by Siemens AG. HIT has been in operation since 2009 and MIT has been in operation since 2015.

    RayStation was selected jointly by clinicians and researchers at HIT, MIT, Heidelberg University Hospital and the German Cancer Research Center (DKFZ), and the system will be used across the four centers. The decision was motivated by RayStation’s outstanding functionality and comprehensive support for the ion treatment technique as well as its capacity to plan for photon linacs and the TomoTherapy delivery system on the same software platform. The full RayStation installation compromises modules for proton, carbon ion and helium ion pencil beam scanning with robust biological optimization using the LEM and MKM models for radiobiological effect.

    This order is a prerequisite for also providing Helium pencil beam scanning support in RayStation to HIT. Such an agreement is under discussion with HIT and is expected to be finalized during 2018.

    Jürgen Debus, Prof. Dr.med. Dr.rer.nat. at the Heidelberg University Hospital says: “RayStation will give us ultimate flexibility to optimize the treatment plans for our patients and seamlessly integrate proton, ion and photon plans."

    Johan Löf, CEO of RaySearch, says: “A major strength of RayStation is the ability to consolidate treatment planning for diverse treatment techniques and machines. RaySearch is committed to supporting the latest clinical approaches, and we are pleased to meet the wide-ranging needs of HIT and MIT, which are truly at the forefront of cancer treatment.”

    The majority of the order will be delivered and generate income during the second quarter of 2018. 

    About HIT and MIT
    Heidelberg Ion Beam Therapy Center (HIT) and Marburg Ion Beam Therapy Center (MIT) are jointly run advanced cancer treatment facilities located in Southwest Germany. HIT at Heidelberg University Hospital was the first ion-beam therapy center in Europe to be integrated into a hospital facility and has treated more than 4,000 patients since it opened in 2009. MIT started operations in 2015, becoming Germany's second and the world's third heavy-ion therapy facility. The center’s activities are supported by University Hospital Heidelberg and the University Hospital of Giessen and Marburg.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy*. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com 

    PDF

    Two major orders for RayStation from North America

    PDF

    RaySearch Laboratories AB (publ) has received major orders for RayStation from two radiation therapy clinics in North America. The combined order value of 6.4 MUSD (excluding service agreements), corresponding to approximately 53 MSEK, has to a large extent been delivered and is expected to generate revenue of approximately 38 MSEK in the first quarter of 2018. The remaining order value will generate revenue during the coming 15 months.

    This information is information that RaySearch Laboratories AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below on March 31, 2018 at 11.30 CET.

    For further information, please contact:

    Johan Löf, President and CEO           Tel:: +46 8 510 530 00      Email: johan.lof@raysearchlabs.com
    Peter Thysell, CFO                             Tel: +46 70 661 0559        Email: peter.thysell@raysearchlabs.com

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. In December 2017; the company launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    PDF

    Share conversion in RaySearch Laboratories AB (publ)

    PDF

    During March 2018, 200,000 Class A shares were converted to Class B shares, at the request of a shareholder. The total number of votes in RaySearch thereafter amounts to 110,377,548 votes. The total number of registered shares in RaySearch amounts to 34,282,773 shares, out of which 8,454,975 are Class A shares and 25,827,798 are Class B shares.

    According to RaySearch Laboratories AB’s (publ) Articles of Association, owners of Class A shares have the right to have such shares converted to Class B shares. A conversion reduces the number of votes in the company. When a conversion has been carried out, RaySearch is obligated by law to disclose information on changes resulting from the conversion.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    This information is information that RaySearch Laboratories AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 08.30 CET on 29 March 2018.

    PDF

    United Imaging Healthcare and RaySearch join forces

    PDF

    Shanghai United Imaging Healthcare Co. Ltd. (UIH) and RaySearch Laboratories AB (publ) (RaySearch) have entered into a collaboration within which RaySearch’s treatment planning system RayStation* and radiation oncology system RayCare* will be adapted to support the UIH linear accelerators.

    Within a few short years, UIH has become a leading vendor of advanced imaging equipment, including CT, PET-CT and MRI systems. Last November, UIH introduced their first radiation therapy system, the uRT-linac506C, at CSTRO in Beijing. This hybrid CT-linac is the world’s first medical linear accelerator with fully-integrated diagnostic-quality CT imaging. It is designed from the ground-up to support adaptive radiation therapy re-planning and provides the highest precision soft-tissue-based image-guidance.

    RayStation already supports a broad range of treatment machines, radiation therapy modalities, and treatment techniques. Since day one, RayStation has focused on adaptive radiation therapy (ART), recognizing it as key to implementing personalized care and optimizing treatment outcomes. To perform ART, RayStation has a found a perfect partner in the UIH CT-linac, since the latter combines full treatment-plan-quality imaging with the latest treatment capabilities for photon therapies. The digital workflows in RayCare that are tailored for efficient adaptive radiation therapy, make ART even more accessible to all types of clinics. UIH’s CT-linac, as well as their standard linac, will be the first conventional photon linacs to be supported by RayCare.

    Johan Löf, CEO and founder of RaySearch Laboratories, says: “There has been a lack of competition in the space of conventional linacs for a long time and I very much welcome that UIH has taken the step into this market. Their CT-linac, in particular, is a great example of a sensible combination of diagnostic imaging and a therapeutic device and I look forward to adding it, as well as the standard UIH linac, to our repertoire of supported treatment systems.”

    Cheng Ni, CEO of UIH’s Radiation Therapy Business Unit, remarked: “This collaboration with RaySearch will enable us to provide a strong software suite as an option to a wide range of clinics, including the most demanding academic centers in the world. It makes it possible for clinics to use our ground-breaking CT-linac in conjunction with other delivery systems inside a single unified software platform.”
      

    About UIH
    Shanghai United Imaging Healthcare Co. Ltd. manufactures medical imaging systems and equipment. UIH was founded 2011 and the headquarter is in Shanghai’s Jiading district. Their mission is to provide medical institutions with a full range of healthcare solutions, from diagnostic imaging and radiation therapy equipment to service, training and medical IT.
      

    About uRT-linac506c
    uRT-linac506C is a fully integrated CT-linac that combines a linear accelerator with a diagnostic CT imager. Designed for the levels of patient throughput required by the world’s busiest therapy centers, the uRT-linac506C includes advanced imaging capabilities without compromising workflow efficiency or treatment performance. The system enables fraction-to-fraction personalized radiotherapy, since adjustments to the treatment plan can be made at any point during the treatment course. Using a single platform, in addition to image-guidance, clinics can perform treatment simulation without a separate CT simulator, or the need to send patients to the radiology department for imaging.
      

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy*. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.
      

    About RayCare
    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.
      

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.
      

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    PDF

    WPE brings PBS aperture planning with Monte Carlo dose calculation to clinical use

    PDF

    The West German Proton Therapy Centre in Essen (WPE) has clinically introduced the Monte Carlo dose calculation method for proton pencil-beam scanning. The subsidiary of University Hospital Essen, WPE is a pioneering institute and was the first proton center in Europe to use RayStation for treatment planning.

    WPE treated it first patients in 2013 and has used RayStation for all treatment planning since 2015. WPE has now become the European pioneer of Monte Carlo dose calculation in RayStation*, having recently treated the first patients planned with this method for dose calculation.

    The Monte Carlo method enables superior prediction of the dose distribution for each patient. A key feature of RayStation’s Monte Carlo dose engine is that it allows for plan optimization in pencil-beam scanning mode in conjunction with collimating patient-specific apertures. The addition of a brass aperture sharpens the lateral dose fall-off, yielding a highly conformal shaping of dose to the target volume.

    Prof. Dr. Beate Timmermann, Director of the Clinic for Particle Therapy at WPE, says: “The combination of pencil beam scanning and apertures enhances our technical options to keep the high-dose regions away from critical structures. We opt for this technique in selected brain tumor cases where organs at risk are near the target volume.”

    Johan Löf, CEO of RaySearch, says: “WPE has a history of firsts and it is gratifying to see the first patient treatment using Monte Carlo dose calculation in Europe. Monte Carlo complements the precision of proton therapy, and the dose engine in RayStation strikes the optimal balance between accurate physics modeling and speed, making it highly effective in clinical workflows. RaySearch has a strong focus on proton therapy, and we aim to keep customers at the forefront by providing the leading functionality.”


    About WPE

    The West German Proton Therapy Centre in Essen (WPE) is a leading institution for proton therapy in Germany and one of the most advanced proton therapy centers in the world. A team of specialists, including doctors, radiation therapists and medical physicists, work together to treat patients with sensitive or deeply located tumors that are either difficult or impossible to operate on. The treatment of children is also a particular specialty. WPE is a subsidiary of University Hospital Essen and thus part of the largest oncological center in Germany – the West German Cancer Centre (WTZ) – and benefits from the expertise of all oncology disciplines.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy*. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com 

    PDF

    First clinic now live with RayCare

    PDF

    RaySearch recently announced the first clinical release of RayCare*, the next-generation oncology information system (OIS). The company is proud to announce that Iridium Cancer Network in Belgium has now started using RayCare 1 clinically to manage its treatment planning workflows, just two months after the clinical release of the system. Iridium is a pioneering clinic that has made a strong contribution to the development of RayCare, particularly with regard to features that will support coordinated activities between different institutions.

    The aim with RayCare is to create an innovative OIS that will support comprehensive cancer care. RayCare will eventually provide one workflow to connect all the oncology disciplines, enabling users to coordinate tasks fluidly and ensure optimal use of resources. Key features of RayCare 1 include task-management support for oncology workflows and an integrated planning experience in combination with RayStation 7*. Integrated communication and documentation functions are designed to ensure efficient handovers between professionals.

    Piet Dirix, MD, PhD, radiation oncologist at Iridium Cancer Network, says: “Our core mission is to contribute to an innovating radiotherapy center for integrated care. RayCare is essential to that mission, since this new OIS is designed to provide comprehensive cancer care in an extremely safe and efficient way, while fully involving patients in their treatment. The collaboration between RaySearch, Iridium and other hospitals throughout the world in developing this system has resulted in an OIS that is highly customizable. RayCare was tailored to our specific needs right from the start.”

    Eeva-Liisa Karjalainen, RayCare Project Manager, says: “RayCare will enable Iridium to use resources more efficiently and free up time for patient care. The workflows are tailored to Iridium’s processes, which makes it possible to automate time-consuming manual steps such as data import/export, task handovers and image management. This supports optimal care for each individual while reducing the burden of clinical documentation.”

    Johan Löf, CEO of RaySearch, says: “It is a dream come true to see this first clinical adoption of RayCare. The system has been designed from the ground up to meet the needs of diverse cancer centers to enable them to give the best possible treatment to their cancer patients. It is unique in supporting integrated workflows based on each patient’s need. RayCare is a truly collaborative effort made possible by the clinical expertise and high engagement of Iridium and our other clinical partners.”
         

    About Iridium Cancer Network
    The Iridium Cancer Network consists of a close collaboration in radiation oncology, and to a lesser extent medical oncology and hematology, between all 7 hospitals in the Antwerp region (GZA hospital group, ZNA hospital group, UZA, AZ KLINA, AZ Nikolaas, AZ Monica, and AZ St Jozef). There is a single radiation therapy department, which treats around 5 300 patients annually. Consequently, Iridium is by far the largest radiation therapy department in Belgium.

    About RayCare
    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    PDF

    MD Anderson and RaySearch announce strategic alliance to advance radiation therapy of cancer

    PDF

    The University of Texas MD Anderson Cancer Center and RaySearch Laboratories today announced a strategic alliance with the aim of enhancing cancer radiation therapy through several initiatives, including more precisely targeting of tumors and improving upon, and making more available, an existing radiation therapy called adaptive radiation therapy (ART), currently only used at highly specialized care centers.

    Successful radiation therapy depends on the ability to delineate the precise tumor location. Since most radiation treatments are delivered over several weeks, a number of variables can compromise treatment accuracy. Traditionally, additional margins are set around the target area to allow for tumor movement and variations in how patients are positioned during treatment.

    However, these margins do not always compensate for unexpected changes in the tumor and surrounding normal tissue over the full course of radiation treatment. Adaptive radiation therapy (ART) uses frequent imaging to give an up-to-date assessment of physical changes and enable precisely tailored treatment for each patient.

    The partnership, which builds upon a previously established relationship between RaySearch and MD Anderson centered on RayCare®, RaySearch’s new oncology information system, combines MD Anderson’s clinical data and expertise with the latest technology and platforms available through RaySearch and will focus on the following areas:

    • Integration of advanced imaging into the treatment planning process to help define the tumor targets better.
    • Management of changes in the tumor that may occur during treatment, and monitoring and adjusting treatment to accommodate each patient’s individual circumstances at any point during therapy.
    • Building software components with the aim of creating a new standard of care in radiation therapy.

    “The technology to perform adaptive radiation therapy has been around for a number of years and studies have demonstrated its advantages,” said Caroline Chung, M.D., assistant professor of Radiation Oncology at MD Anderson. “However, it is a complex process that has not yet been broadly adopted in clinical practice and is largely limited to highly specialized care centers. The goal of this collaboration is to establish a methodology and workflow, clinically tested at MD Anderson, which can be streamlined and automated to enable adaptive radiation therapy on a larger scale.”

    The combination of advanced imaging data, including platforms such as RayCare and the treatment planning system RayStation, will be vital to improving the delineation of tumors. Together, this provides a novel opportunity for more personalized treatment and the development of digital workflows has the potential to improve patient care at MD Anderson and other cancer care facilities around the world.

    “This strategic partnership between MD Anderson and RaySearch is an incredibly important milestone for RaySearch,” said Johan Löf, Ph.D., CEO and founder of RaySearch. “It is one of the most ambitious collaborations that we have ever engaged in. With RayStation and RayCare as the technological platforms, paired with the expertise of MD Anderson, I believe that we can make tremendous progress toward our vision of a world where cancer is conquered.”
        
      
    About MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is located in central Houston in the Texas Medical Center. MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 45 National Cancer Institute-designated comprehensive cancer centers today. U.S. News & World Report’s “Best Hospitals” survey has ranked MD Anderson the nation’s top hospital for cancer care. MD Anderson has been ranked the leading cancer hospital for 11 of the past 14 years. The institution has been named one of the nation's top two hospitals for cancer care every year since the survey began in 1990.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton and carbon ion therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com 

    MD Anderson Media Contact:
    Ron Gilmore
    Office: +1 713-745-1898
    Cell: +1-575-915-5790
    Email: rlgilmore1@mdanderson.org

    PDF

    Year-end Report January 1 - December 31, 2017

    PDF

    RaySearch Laboratories AB (publ)

    “In 2017, net sales rose 10 percent to SEK 585 M (531). The operating margin declined to 27 percent (38) due to lower growth for RayStation®, negative currency effects due to the weakening of the USD and higher costs due to the company’s investments in the global marketing organization and in research and development. RayStation 7 and RayCare® 1 were launched as planned and we have already secured the first order for RayCare,” says Johan Löf, President and CEO of RaySearch.

    FOURTH QUARTER (OCTOBER-DECEMBER 2017) 

    • Net sales SEK 204.9 M (191.4), of which revenues from RayStation/RayCare SEK 192.6 M (174.8)  
    • Profit after tax SEK 72.3 M (75.9) and earnings per share before/after dilution SEK 2.11 (2.21) 
    • Operating profit SEK 98.7 M (100.2) 
    • Cash flow SEK 34.6 M (56.6) 
    • Order intake excl. service agreements SEK 192.6 M (189.0), of which RayStation/RayCare SEK 183.2 M (176.3)  
    • Order backlog for RayStation/RayCare was SEK 50.0 M (67.6) at the end of the period

    TWELVE MONTHS (JANUARY-DECEMBER 2017) 

    • Net sales SEK 585.1 M (531.5), of which revenues from RayStation/RayCare SEK 531.7 M (476.0)  
    • Profit after tax SEK 117.6 M (151.4) and earnings per share SEK 3.43 (4.42) 
    • Operating profit SEK 159.7 M (200.0) 
    • Cash flow SEK 19.1 M (26.2) 
    • Order intake excl. service agreements SEK 508.4 M (501.1), of which RayStation/RayCare SEK 467.8 M (461.0)  
    • The Board of Directors proposes that no dividend be paid for 2017

    SIGNIFICANT EVENTS DURING THE FOURTH QUARTER 

    • RayStation was selected by a number of leading cancer clinics, for example, Sharp Grossmont Hospital, Anderson Regional Cancer Center and Erlanger Hospital in the US, Hôtel-Dieu de Lévis in Canada, Lausanne University Hospital (CHUV) in Switzerland, Centre Francois Baclesse in Luxemburg, Charing Cross Hospital and Hammersmith Hospital in the UK, and Maria Sklodowska-Curie Memorial Cancer Center in Poland. In addition, RayStation was also selected for a new carbon ion center at the Yamagata University Hospital in Japan and for the Apollo Proton Cancer Center in Chennai, which is the first proton therapy center in India. 
    • RayStation 7* was released with support for Mevion HYPERSCAN and integration with RayCare. RaySearch also launched µ-RayStation, a new version of the treatment planning system, which is specially adapted for pre-clinical research on small animals. 
    • RayCare 1, the next-generation oncology information system (OIS), was released as planned and the company has secured the first order for RayCare from Anderson Regional Cancer Center in the US.
          

    NO SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD 

    The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on February 15, 2018 at 7:45 a.m. CET.
       

    FOR FURTHER INFORMATION, PLEASE CONTACT:
    Johan Löf, President and CEO    Tel: +46 8 510 530 00     E-mail: johan.lof@raysearchlabs.com
    Peter Thysell, CFO    Tel: +46 70 661 05 59     E-mail:
    peter.thysell@raysearchlabs.com
      

    ABOUT RAYSEARCH
    RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. The company develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which was launched in December 2017 and comprises a new product area for RaySearch. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
    More information about RaySearch is available at
    www.raysearchlabs.com.

    * Regulatory approval is required in some markets.

    PDF

    Year-end Report January 1 - December 31, 2017

    PDF

    RaySearch Laboratories AB (publ)

    “In 2017, net sales rose 10 percent to SEK 585 M (531). The operating margin declined to 27 percent (38) due to lower growth for RayStation®, negative currency effects due to the weakening of the USD and higher costs due to the company’s investments in the global marketing organization and in research and development. RayStation 7 and RayCare® 1 were launched as planned and we have already secured the first order for RayCare,” says Johan Löf, President and CEO of RaySearch

    FOURTH QUARTER (OCTOBER-DECEMBER 2017) 

    • Net sales SEK 204.9 M (191.4), of which revenues from RayStation/RayCare SEK 192.6 M (174.8)  
    • Profit after tax SEK 72.3 M (75.9) and earnings per share before/after dilution SEK 2.11 (2.21) 
    • Operating profit SEK 98.7 M (100.2) 
    • Cash flow SEK 34.6 M (56.6) 
    • Order intake excl. service agreements SEK 192.6 M (189.0), of which RayStation/RayCare SEK 183.2 M (176.3)  
    • Order backlog for RayStation/RayCare was SEK 50.0 M (67.6) at the end of the period

    TWELVE MONTHS (JANUARY-DECEMBER 2017) 

    • Net sales SEK 585.1 M (531.5), of which revenues from RayStation/RayCare SEK 531.7 M (476.0)  
    • Profit after tax SEK 117.6 M (151.4) and earnings per share SEK 3.43 (4.42) 
    • Operating profit SEK 159.7 M (200.0) 
    • Cash flow SEK 19.1 M (26.2) 
    • Order intake excl. service agreements SEK 508.4 M (501.1), of which RayStation/RayCare SEK 467.8 M (461.0)  
    • The Board of Directors proposes that no dividend be paid for 2017

    SIGNIFICANT EVENTS DURING THE FOURTH QUARTER 

    • RayStation was selected by a number of leading cancer clinics, for example, Sharp Grossmont Hospital, Anderson Regional Cancer Center and Erlanger Hospital in the US, Hôtel-Dieu de Lévis in Canada, Lausanne University Hospital (CHUV) in Switzerland, Centre Francois Baclesse in Luxemburg, Charing Cross Hospital and Hammersmith Hospital in the UK, and Maria Sklodowska-Curie Memorial Cancer Center in Poland. In addition, RayStation was also selected for a new carbon ion center at the Yamagata University Hospital in Japan and for the Apollo Proton Cancer Center in Chennai, which is the first proton therapy center in India. 
    • RayStation 7* was released with support for Mevion HYPERSCAN and integration with RayCare. RaySearch also launched µ-RayStation, a new version of the treatment planning system, which is specially adapted for pre-clinical research on small animals.  
    • RayCare 1, the next-generation oncology information system (OIS), was released as planned and the company has secured the first order for RayCare from Anderson Regional Cancer Center in the US
         

    NO SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD 

    The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on February 15, 2018 at 7:45 a.m. CET.
       

    FOR FURTHER INFORMATION, PLEASE CONTACT:
    Johan Löf, President and CEO    Tel: +46 8 510 530 00     E-mail: johan.lof@raysearchlabs.com
    Peter Thysell, CFO    Tel: +46 70 661 05 59     E-mail:
    peter.thysell@raysearchlabs.com
      

    ABOUT RAYSEARCH
    RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. The company develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which was launched in December 2017 and comprises a new product area for RaySearch. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
    More information about RaySearch is available at www.raysearchlabs.com.
      

    * Regulatory approval is required in some markets.

    PDF

    Mitchell Cancer Institute, US, selects RayStation for TomoTherapy

    PDF

    The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Alabama, has selected RayStation* as its treatment planning system for the TomoTherapy ® System. The center also treats patients using a CyberKnife ®System and will use RayStation* for this in the future.

    MCI’s radiation therapy service is equipped with state-of-the-art Accuray´s CyberKnife and TomoTherapy System, as well as a 64-slice PET-CT scanner. The center was initially interested in RayStation’s forthcoming support for the CyberKnife System, but quickly saw that the system could meet all of its treatment planning needs into the future, including the TomoTherapy System.

    Dr. Weisi Yan, Director of the CyberKnife Program at MCI, says: “We were very impressed by the capabilities and user-friendliness of RayStation. As a leading-edge treatment center, we need the best possible technology in order to deliver outstanding care and maximize efficiency. RayStation will help us to achieve our goals.”

    Hal Hopper, Manager of MCI’s Department of Radiation Oncology, says: “RayStation is fast and effective in planning treatments for all possible techniques we are likely to offer. It is much less labor-intensive than other systems we have used. With RayStation, the physician can choose the best course of treatment more quickly.”

    Johan Löf, CEO of RaySearch, says: “MCI shares our vision of continuously advancing cancer treatment. We are very pleased to be able to meet their requirements for advanced clinical techniques as well as optimized workflows and use of resources.”
        

    About MCI
    Founded in 2000, MCI provides cancer treatment in three locations: MCI headquarters in Mobile, the MCI Kilborn Clinic in Fairhope and Monroe County Hospital in Monroeville. The center’s researchers and clinicians focus daily on the battle against cancer serving a potential catchment population of more 4.1 million people, with a singular focus of advancing cancer diagnosis, treatment and prevention in the region and beyond. Since its establishment, the center’s strategic goal has remained constant: to achieve competitiveness for future designation as an NCI Comprehensive Cancer Center and to achieve self-sustaining, long-term financial viability.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy*. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com 

    PDF

    RayStation selected for India’s first Proton Center

    PDF

    Apollo Hospitals, Asia´s foremost integrated healthcare provider, as selected RayStation for a new proton therapy center in Chennai – the first such facility in India. The center will be equipped with IBA’s Proteus®PLUS treatment delivery system in a multi-room configuration. The setup will comprise two gantry treatment rooms and one fixed-beam treatment room, each fitted with advanced pencil beam scanning and cone beam CT technology.

    Following an extensive review of the leading systems available, RayStation was selected as the treatment planning system for the new center, which is scheduled to treat its first patients in September 2018. The choice was motivated by RayStation’s comprehensive functionality and support for all major treatment delivery systems, and RaySearch’s world-leading position in proton therapy treatment planning. An important goal for Apollo Hospitals is to unify the treatment planning workflow. The agreement includes modules for deformable registration, dose tracking, adaptive therapy and multi-criteria optimization.

    Preetha Reddy, Vice Chairperson, Apollo Hospitals Groups says: “Our resolute commitment is to make cancer conquerable and the Apollo Proton Cancer Center in Chennai underscores this etos. Over the years, we have continuously introduced the most advanced cancer care for our patients and Apollo has been honored with the trust of individuals from over 140 countries.”
    Ms. Reddy added, “Innovative technologies have been a hallmark of our cancer care protocols with RayStation reaffirms our continued investments into the best available care for modalities for our patients.”

    Johan Löf, CEO of RaySearch, says: “We are delighted to have been chosen by Apollo Hospitals for their ground-breaking introduction of proton therapy in India. Apollo shares our view of the many benefits in having a single treatment planning system for all treatment machines, and our partnership will result in high efficiency and outstanding patient care. This installation reinforces our strong and growing presence in the APAC region and our commitment to supporting the widest possible range of treatment machines.”

         

    About Apollo Hospitals
    Apollo Hospitals is widely recognized as a pioneer of private healthcare in India and established the country’s first corporate hospital in 1983. Today, it is one of Asia’s foremost integrated healthcare services providers, operating 64 hospitals as well as pharmacies, primary care and diagnostic clinics.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton and carbon ion therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    PDF

    Beaumont Hospital, US, extends RayStation to Photon Therapy

    PDF

    Beaumont Hospital in Royal Oak, Michigan, has chosen to make a significant extension to its RayStation installation, which will include photon therapy in addition to proton. RayStation will be used for photon planning at Beaumont Hospital in Dearborn, where new linacs will be commissioned for the system. The purchase also includes additional functionality and licenses for proton therapy at Beaumont Hospital, Royal Oak.

    The nationally recognized cancer program at Beaumont is based on the latest treatment technologies. Beaumont initially purchased RayStation for proton therapy in 2014, and advanced features such as adaptive therapy and deformable registration are key elements of its workflow.

    “We are excited about having the opportunity to extend RayStation to our photon business,” says Craig Stevens, M.D., Ph.D., Radiation Oncologist and Chairman, Radiation Oncology at Beaumont. “It will allow us to mix proton and photon planning, ultimately streamlining and improving efficiency.”

    Xuanfeng Ding, Ph.D., Lead Proton Physicist, adds: “We often create both a photon and proton plan and compare side-by-side to determine the best treatment option for each patient. Deformable registration has been a great help in our proton center, helping us to evaluate previous dose and generate the plan sum on the current CT. In combination with the adaptive functionality, it definitely helps improves quality of patient care and workflow efficiency.

    Johan Löf, CEO of RaySearch, says: “Beaumont has an outstanding track record in using advanced technology to ensure the optimal treatment method for each patient. RayStation is an excellent fit for this approach, with comprehensive functionality to support cutting-edge techniques and the widest range of treatment machines. I look forward to a successful partnership that will benefit many patients in Michigan.”
     

    About Beaumont Hopsital
    Beaumont is Michigan’s largest healthcare system, established in 2014 to provide patients in Southeast Michigan with compassionate, extraordinary care. Beaumont Health’s culture of caring partnerships and its care delivery model of patient- and family-centered care demonstrates its commitment to engaging patients, families and the community to promote continuous healthcare improvements. With 8 hospitals, 174 health centers, close to 5,000 physicians and 38,000 employees, Beaumont Health contributes to the health and well-being of residents throughout Southeast Michigan and beyond.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton and carbon ion therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
     

    To learn more about RaySearch, go to: www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com

    PDF

    RayStation selected for Charing Cross Hospital and Hammersmith Hospital in London

    PDF

    Imperial College Healthcare NHS Trust in London, UK, has chosen RayStation as the sole treatment planning system for two sites in London: Charing Cross Hospital and Hammersmith Hospital. RayStation was selected as the best solution following a thorough evaluation of all potential treatment planning systems on the market.

    The Imperial College Healthcare NHS Trust operates five hospitals in London, plus a range of community health services. Its radiation therapy services are provided at Charing Cross Hospital and Hammersmith Hospital. RayStation will replace two different treatment planning systems currently in use at the hospitals.

    The two hospitals will use RayStation for all radiation therapy treatment planning activities, as well as all pre-treatment virtual simulation. RayStation will replace the hospitals’ current standalone system for virtual simulation. The purchase comprises a broad range of functionality, including 3D-CRT, IMRT, VMAT, multi-criteria optimization, automated breast planning and adaptive planning.

    Johan Löf, CEO of RaySearch, says: “We are very pleased to support the needs of these two leading London hospitals. The aim with RayStation is to provide the most comprehensive functionality. This makes it possible for clinics to consolidate multiple systems, increase efficiency and reduce the need for staff training. We look forward to a successful partnership.”

    About Imperial College Healthcare NHS Trust
    Imperial College Healthcare NHS Trust provides acute and specialist healthcare for a population of nearly two million people in north west London, and more beyond. The Trust has five hospitals in London – Charing Cross, Hammersmith, Queen Charlotte’s & Chelsea, St Mary’s and The Western Eye – and runs a growing number of community services. With its academic partner, Imperial College London, the trust is one of the UK’s 11 academic health science centres, working to ensure the rapid translation of research for better patient care and excellence in education.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy*. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
      

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    PDF

    RaySearch receives first order for the RayCare™ Oncology infomation System

    PDF

    Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, USA, has placed the first order for RayCare*, a next-generation oncology information system (OIS). RayCare is an innovative system designed to support comprehensive cancer care. It integrates seamlessly with the RayStation treatment planning system, but that’s just the start – RayCare will connect all the oncology disciplines, enabling users to fluidly coordinate tasks and ensure optimal use of resources.

    Over subsequent releases, RayCare will evolve into a machine learning OIS with unique capabilities to coordinate oncology tasks, supporting comprehensive cancer care organized around each patient’s needs. Many cancer patients receive a combination of treatment types, driving the need for combined workflows for radiation therapy, chemotherapy and surgery.

    ARCC decided to map out a future for their clinical workflows that would support advanced technology and data driven decision making. They determined that the best approach would be to move to a new treatment planning system and a new oncology information system that together would support their linacs and TomoTherapy systems, in order to have a unified platform for planning, treatment and assessment.

    Paul King, Chief Medical Physicist, says: “We evaluated all the leading systems and were extremely impressed by the possibilities of RayCare. It delivers on everything we were looking for. Getting all of these pieces integrated together will help us tremendously. RaySearch is an innovator with the leading technology in this area and I have great confidence in their ability to meet our needs into the future. We will keep exploring the cutting-edge of technology in order to secure the best possible care for our patients. RayCare will help us achieve this aim.”

    Dr. Scott Anderson, Radiation Oncologist and Medical Director, says: “We find ourselves in the position that we are at a decision point where we can stay static in a satisfactory status quo, or we can move into what will be the standard in the future. We look forward to working with RaySearch Laboratories to shape the future of longitudinal cancer care. Survivorship and tracking patients long term will be the benchmarks of cancer care moving forward. This new system that is being developed will give us better tools to do so.”

    Johan Löf, CEO of RaySearch, says: “I am delighted by this first RayCare order and very excited about helping ARCC achieve an efficient, integrated system for the future. RayCare is fundamentally different compared to other OIS systems, and we have invested a great deal of time and effort into creating something that will truly change the way that cancer is treated. Our goal is to advance cancer treatment with high-performance tools that combine treatment planning, workflow and data management, resource optimization, machine learning and follow-up in an effective way.”

    About Anderson Regional Cancer Center
    Anderson Regional Cancer Center in Meridian, Mississippi, is a state-of-the-art cancer center equipped to provide innovative treatment for all types of cancer. The center sees about 180 outpatients a day for radiation or chemotherapy treatments and serves a geographical area across East Mississippi and West Alabama.

    About RayCare
    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.


    To learn more about RaySearch, go to:
    www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com
     

    PDF

    RayStation selected for new Carbon ion therapy center in Japan

    PDF

    RayStation* has been chosen as the treatment planning system for a new carbon-ion therapy facility which is under construction at Yamagata University Hospital in northern Japan. The order represents the first RayStation carbon ion installation in Japan.

    Carbon ion therapy is an advanced form of radiation therapy that precisely targets cancer cells with minimal damage to surrounding tissue. The technique uses a carbon ion beam, accelerated up to 70% of the speed of light. Carbon ion beams are highly effective in destroying cancer cells, and the technique can be effective for cancers that are resistant to X-rays. An additional advantage is that the treatment period often is shorter than for other forms of radiation therapy.

    RayStation was selected jointly by Yamagata University Hospital and Toshiba, which is supplying the treatment delivery system. The decision was motivated by RayStation’s outstanding functionality and comprehensive support for this cutting-edge treatment technique. The RayStation installation will include modules for carbon pencil beam scanning with robust biological optimization (using both the MKM and LEM models), deformable registration, dose tracking and adaptive therapy.

    The facility expects to treat its first patients by early 2020. Toshiba’s treatment delivery system will comprise two treatment rooms, a fixed-port room and a 360-degree rotating compact superconducting gantry. The facility will be the most compact carbon ion installation in the world, and one of the few integrated into a general hospital.

    Johan Löf, CEO of RaySearch, says: “RaySearch is committed to providing the leading support for cutting-edge techniques such as carbon ion therapy, and we are very pleased to meet the needs of Yamagata University Hospital and Toshiba. RayStation has a strong and growing user base in Japan, and we will continue to focus resources on this technologically advanced market.”
      

    About Yamagata University Hospital
    Yamagata University Hospital is a major general hospital located in Yamagata prefecture, northern Japan. Established in 1976, the hospital offers a wide range of medical specialties, including oncology. The hospital’s clinical cancer center was established in 2007. Yamagata University Hospital works to pursue its philosophy of “deeply humane and reliable medical care.”

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy*. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.
     

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com

    PDF